Amgen Price Target Hike Signals Potential Downside for Investors

Amgen Inc.'s price target has been increased by analysts to $375.89, signaling potential downside of about 4% for investors. This updated forecast is based on estimates from 27 experts who have revised their predictions upwards, with individual targets ranging from $220 to $452 per share.

The consensus rating among covering analysts remains at 'Buy', with a significant number still optimistic about the company's prospects. However, this latest development could cause some concern for those who had been banking on Amgen Inc.'s stock price continuing its upward trajectory.